It’s only fair to share… Pariceract CAS 1919820-28-2 MFC20H30N4O2 MW358.5 g/mol 5,7-dimethyl-N-[trans-4-(pentyloxy)cyclohexyl]pyrazolo[1,5-a]pyrimidine-3-carboxamidebeta-glucocerebrosidase activator, antiparkinsonian, BIA 28-6156, LTI-291, LIT291, LTI-00291, BIA28-6156, LTI- 91, LIT 291, LTI 00291, Gcase activator 1, V9WUN9UUU8 Pariceract (INNTooltip International Nonproprietary Name; developmental code name BIA 28-6156 or LTI-291) is a β-glucocerebrosidase (GCase) activator or positive allosteric modulator which is under development for the treatment of Parkinson’s disease.[1][2][3][4][5] It is taken orally.[1] GCase is a lysosomal enzyme encoded by the gene GBA1.[4][5] Loss-of-function mutations in …
Tag «Antiparkinsonian»
DROXIDOPA
It’s only fair to share… DROXIDOPA ORPHAN DRUG, CAS 23651-95-8, 3916-18-5 ROTATION –FORM (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid 223-480-5 [EINECS], L-Tyrosine, β,3-dihydroxy-, (βR)-, L-Tyrosine, β,3-dihydroxy-, threo- Northera [Trade name] threo-b,3-Dihydroxy-L-tyrosine 1-14-00-00685 [Beilstein], L-threo-3-(3,4-Dihydroxyphenyl)serine, L-Dihydroxyphenylserine, L-DOPS;DOPS, \ Northera, SM5688, L-DOPS|Northera®, |SM-5688, L-threo-dihydroxyphenylserine, L-Threodops L-threo-droxidopa, threo-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid THREO-DIHYDROXYPHENYLSERINE threo-Dopaserine UNII:24A0V01WKS UNII:J7A92W69L7 FDA 2/18/2014, FDA approves Northera to treat neurogenic orthostatic hypotension Properties: Crystals from ethanol and ether, mp 232-235° (dec). [a]D20 -39° …